Glenmark Pharma Results Analysis

Operating Revenue for Q2FY26 is Rs. 6,047 Crs., 76.1% growth YoY, Total Income is Rs. 6,248 Crs., 79.9% growth YoY, EBITDA is Rs. 2,360 Crs., 292% growth YoY, EBITDA Margin is 39.02% improved by 2,149 Basis points YoY, PBT Rs. 967 Crs., 104.7% growth YoY, PAT Rs. 610 Crs. 72.2% growth YoY. On QoQ basis Op. Revenue is up by 85.2%, Total Income is up by 89.8%, EBITDA is up by 306%, EBITDA Margin also improved by 2124 basis points, PBT is up by 912% and PAT is also up by 1200%. Post Q2, Glenmark is entering a new phase called Glenmark 3.0… a very strong revenue growth phase of 12% to 15%, strong operating margins of 23% going forward, targeted to go up to 25-plus percent… zero gross debt in FY ’26… industry best ROCs and ROEs in FY ’27 and beyond. Guidance for FY27 revenue: INR 17,000–18,000cr; EBITDA margin: “23% immediately… moving up to 25%.”